Panagiotis-Christos Kotsias

Panagiotis-Christos Kotsias

Auto-generated profile, based on publicly available information

Panagiotis-Christos Kotsias

AstraZeneca AB

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2019 in Journal of Cheminformatics
Verified
Journal Article
Open access
PDF file
OPOleksii Prykhodko
Oleksii Prykhodko
SJSimon Viet Johansson
Simon Viet Johansson
PKPanagiotis-Christos Kotsias
Panagiotis-Christos Kotsias
JAJosep Arús-Pous
Josep Arús-Pous
EBEsben Jannik Bjerrum
Esben Jannik Bjerrum
HCHongming Chen
Hongming Chen
Deep learning methods applied to drug discovery have been used to generate novel structures. In this study, we propose a new deep learning architecture, LatentGAN, which combines an autoencoder and a generative adversarial neural network for de novo molecular design. We applied the method in two scenarios: one to generate random drug-like compounds and another to generate target-biased compounds. Our results show that the method works well in both cases. Sampled compounds from the trained model can largely occupy the same chemical space as the training set and also generate a substantial fraction of novel compounds. Moreover, the drug-likeness score of compounds sampled from LatentGAN is also similar to that of the training set. Lastly, generated compounds differ from those obtained with a Recurrent Neural Network-based generative model approach, indicating that both methods can be used complementarily.

18 May 2020 in Nature Machine Intelligence
Verified
Journal Article
Closed access
PDF file
PKPanagiotis-Christos Kotsias
Panagiotis-Christos Kotsias
JAJosep Arús-Pous
Josep Arús-Pous
HCHongming Chen
Hongming Chen
OEOla Engkvist
Ola Engkvist
CTChristian Tyrchan
Christian Tyrchan
EBEsben Jannik Bjerrum
Esben Jannik Bjerrum

25 November 2019 in ChemRxiv
Verified
Preprint
Open access
PDF file
PKPanagiotis-Christos Kotsias
Panagiotis-Christos Kotsias
JAJosep Arús-Pous
Josep Arús-Pous
HCHongming Chen
Hongming Chen
OEOla Engkvist
Ola Engkvist
CTChristian Tyrchan
Christian Tyrchan
EBEsben Jannik Bjerrum
Esben Jannik Bjerrum
Deep learning has acquired considerable momentum over the past couple of years in the domain of de-novo drug design. Particularly, transfer and reinforcement learning have demonstrated the capability of steering the generative process towards chemical regions of interest. In this work, we propose a simple approach to the focused generative task by constructing a conditional recurrent neural network (cRNN). For this purpose, we aggregate selected molecular descriptors along with a QSAR-based bioactivity label and transform them into initial LSTM states before starting the generation of SMILES strings that are focused towards the aspired properties. We thus tackle the inverse QSAR problem directly by training on molecular descriptors, instead of iteratively optimizing around a set of candidate molecules. The trained cRNNs are able to generate molecules near multiple specified conditions, while maintaining an output that is more focused than traditional RNNs yet less focused than autoencoders. The method shows promise for applications in both scaffold hoping and ligand series generation, depending on whether the cRNN is trained on calculated scalar molecular properties or structural fingerprints. This also demonstrates that fingerprint-to-molecule decoding is feasible, leading to molecules that are similar – if not identical – to the ones the fingerprints originated from. Additionally, the cRNN is able to generate a larger fraction of predicted active compounds against the DRD2 receptor when compared to an RNN trained with the transfer learning model.

23 September 2019 in ChemRxiv
Verified
Preprint
Open access
PDF file
PKPanagiotis-Christos Kotsias
Panagiotis-Christos Kotsias
JAJosep Arús-Pous
Josep Arús-Pous
HCHongming Chen
Hongming Chen
OEOla Engkvist
Ola Engkvist
CTChristian Tyrchan
Christian Tyrchan
EBEsben Jannik Bjerrum
Esben Jannik Bjerrum
Deep learning has acquired considerable momentum over the past couple of years in the domain of de-novo drug design. Particularly, transfer and reinforcement learning have demonstrated the capability of steering the generative process towards chemical regions of interest. In this work, we propose a simple approach to the focused generative task by constructing a conditional recurrent neural network (cRNN). For this purpose, we aggregate selected molecular descriptors along with a QSAR-based bioactivity label and transform them into initial LSTM states before starting the generation of SMILES strings that are focused towards the aspired properties. We thus tackle the inverse QSAR problem directly by training on molecular descriptors, instead of iteratively optimizing around a set of candidate molecules. The trained cRNNs are able to generate molecules near multiple specified conditions, while maintaining an output that is more focused than traditional RNNs yet less focused than autoencoders. The method shows promise for applications in both scaffold hoping and ligand series generation, depending on whether the cRNN is trained on calculated scalar molecular properties or structural fingerprints. This also demonstrates that fingerprint-to-molecule decoding is feasible, leading to molecules that are similar – if not identical – to the ones the fingerprints originated from. Additionally, the cRNN is able to generate a larger fraction of predicted active compounds against the DRD2 receptor when compared to an RNN trained with the transfer learning model.

23 September 2019 in ChemRxiv
Verified
Preprint
Open access
PDF file
OPOleksii Prykhodko
Oleksii Prykhodko
SJSimon Viet Johansson
Simon Viet Johansson
PKPanagiotis-Christos Kotsias
Panagiotis-Christos Kotsias
JAJosep Arús-Pous
Josep Arús-Pous
EBEsben Jannik Bjerrum
Esben Jannik Bjerrum
HCHongming Chen
Hongming Chen
Deep learning methods applied to drug discovery have been used to generate novel structures. In this study, we propose a new deep learning architecture, LatentGAN, which combines an autoencoder and a generative adversarial neural network for de novo molecular design. We applied the method in two scenarios: one to generate random drug-like compounds and another to generate target-biased compounds. Our results show that the method works well in both cases: sampled compounds from the trained model can largely occupy the same chemical space as the training set and also generate a substantial fraction of novel compounds. Moreover, the drug-likeness score of compounds sampled from LatentGAN is also similar to that of the training set. Lastly, generated compounds differ from those obtained with a Recurrent Neural Network-based generative model approach, indicating that both methods can be used complementarily.